BBOT insider granted 357,177 options at $9.59 — time‑based vesting

BridgeBio Oncology Therapeutics reported an insider award to its Chief Medical & Development Officer and director, Ben Yong.

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics reported an insider award to its Chief Medical & Development Officer and director, Ben Yong. The Form 4 discloses an award of a stock option to purchase 357,177 shares of common stock at an exercise price of $9.59. The option grant is exercisable consistent with a time-based vesting schedule: vesting commences from an August 11, 2025 vesting commencement date, with an initial fractional vesting linked to the date a Form S-8 registration is filed and becomes effective and then monthly vesting thereafter until fully vested on the fourth anniversary of the vesting commencement date, subject to continuous service. Following the reported transaction the reporting person directly beneficially owns 357,177 shares underlying the option.

Positive

• Significant alignment of interests between management and shareholders via a large time-based option grant
• Vesting linked to Form S-8 which delays transferability until registration, supporting long-term retention

Negative

• Potential dilution if 357,177 options are exercised, magnitude depends on total outstanding shares (not disclosed in this filing)
• Large single grant to an officer/director could raise governance questions about compensation concentration

Insights

Securities Analyst

TL;DR: Insider received a sizable option grant (357,177 shares) at $9.59 with multi-year vesting tied to Form S-8 registration.

The grant aligns senior management incentives with shareholder value by linking vesting to both a registration event and continued service over four years. The exercise price of $9.59 establishes the cost basis for potential future dilution if exercised. Investors should note the grant size relative to outstanding shares (not provided here) to assess dilution impact. The S-8 contingency front-loads vesting only if the registration occurs, which delays liquidity and aligns long-term retention.

Corporate Governance Expert

TL;DR: Grant appears structured to retain and incentivize the reporting officer while conditioning some vesting on an S-8 registration.

The vesting terms combining an S-8-based initial vesting fraction and a standard 48-month monthly schedule reflect common practice to ensure shares become transferable only after a registration statement is effective. This reduces immediate transferability risk and ties economic benefit to a registration milestone plus continued service. From a governance perspective, disclosure is standard and sufficiently detailed about vesting mechanics; materiality depends on company capitalization not disclosed in this filing.

Insider Trade Summary

Grant/Award: 357,177 shares

Grant/Award 1 txn

Insider Ben Yong

Role Chief Med & Dev Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	357,177	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 357,177 contracts (Direct)

Footnotes (1)

1. F1. A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ben Yong report owning in the Form 4 for BBOT?

The Form 4 reports a stock option to purchase 357,177 shares of common stock, with an exercise price of $9.59, and 357,177 shares beneficially owned following the transaction.

What are the vesting conditions for the option disclosed in the BBOT Form 4?

Vesting begins from a Vesting Commencement Date of August 11, 2025, includes an initial fractional vesting tied to the effectiveness of a Form S-8 registration, then vests monthly (1/48th per month) until fully vested on the fourth anniversary, subject to continuous service.

What is the exercise price and term of the option in the BBOT filing?

The option has an exercise price of $9.59. The filing shows an expiration indicator consistent with a ten-year term ending in 08/25/2035 for the underlying awards.

Does the Form 4 indicate whether the award is direct or indirect ownership?

The Form 4 indicates the ownership form is Direct (D) for the 357,177 shares underlying the option.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/28/2025 - 04:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ben Yong

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Med & Dev Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.59	08/26/2025		A		357,177		(1)	08/25/2035	Common Stock	357,177	$0	357,177	D

Explanation of Responses:

1. A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date.

	/s/ Aaron Chan, Attorney-in-Fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.